Slide 1: Agilent Technologies Lasergen Investment Announcement
Agilent Technologies Lasergen Investment Announcement March 7, 2016 1
Slide 2: Safe Harbor
Safe Harbor This presentation contains forward-looking statements (including, without limitation, information and future guidance on the company’s goals, priorities, revenues, demand, growth opportunities, customer service and innovation plans, new product introductions, financial condition, earning
Slide 3: Transaction at a Glance
Transaction at a Glance Agilent Making an $80M Investment in Lasergen • The two companies will collaborate on building a next-generation sequencing solutions workflow for clinical applications supporting Agilent´s diagnostics strategy for cancer and constitutional diseases. • Agilent will join Laser
Slide 4: Lasergen Investment Enables DGG's Stated Strategic Intent
Lasergen Investment Enables DGG’s Stated Strategic Intent • Strategic investment to close a key instrument gap, enabling an integrated clinical workflow solution for cancer and genetic disorder applications • Clinical NGS workflow advances pathology vision of the “diagnostic cockpit” DGG strategy pr
Slide 5: Lasergen Company Profile
Lasergen Company Profile Company overview • Privately held biotechnology company focused on commercializing sequencing technologies • Headquartered in Houston, Texas Team • President & CEO: Mimi Healy, PhD • ~20 employees focused on chemistry, molecular biology, instrumentation and software. Plans t
Slide 6: Deal Structure and Financial Considerations
Deal Structure and Financial Considerations A measured investment with potential to gain a valuable position in a growing market • Agilent presently investing $80M to acquire 48% of the outstanding stock of Lasergen. The remaining shares will continue to be owned by the current shareholders. • $45M